-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 2 A few days ago, the NMPA official website showed that Simcere's mycophenolate mofetil capsules were approved and deemed to have been reviewed.
According to data from Mi Nei.
com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year.
According to data from Mi Nei.
com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year.
Mycophenolate mofetil is an immunosuppressant developed by Roche.
It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
Sales of mycophenolate mofetil at the terminal of public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2019, the sales of mycophenolate mofetil in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in 2020H1, its sales exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year, of which Roche accounted for 60.
7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
39%.
6 billion yuan, an increase of 13.
39% year-on-year, of which Roche accounted for 60.
7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
39%.
Mycophenolate mofetil capsules previously reviewed companies
Source: Mi Nei Net Consistency Evaluation Database
At present, mycophenolate mofetil capsules have been evaluated by 4 companies, including Hisun Pharmaceutical, Tianyin Pharmaceutical, Sino-US Huadong Pharmaceutical and Simcere Pharmaceutical.
With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
Data source: Mi Neiwang database
Medical Network News on March 2 A few days ago, the NMPA official website showed that Simcere's mycophenolate mofetil capsules were approved and deemed to have been reviewed.
According to data from Mi Nei.
com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year.
According to data from Mi Nei.
com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year.
Mycophenolate mofetil is an immunosuppressant developed by Roche.
It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
Sales of mycophenolate mofetil at the terminal of public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2019, the sales of mycophenolate mofetil in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in 2020H1, its sales exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year, of which Roche accounted for 60.
7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
39%.
6 billion yuan, an increase of 13.
39% year-on-year, of which Roche accounted for 60.
7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
39%.
Mycophenolate mofetil capsules previously reviewed companies
Source: Mi Nei Net Consistency Evaluation Database
At present, mycophenolate mofetil capsules have been evaluated by 4 companies, including Hisun Pharmaceutical, Tianyin Pharmaceutical, Sino-US Huadong Pharmaceutical and Simcere Pharmaceutical.
With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
Data source: Mi Neiwang database
Medical Network News on March 2 A few days ago, the NMPA official website showed that Simcere's mycophenolate mofetil capsules were approved and deemed to have been reviewed.
According to data from Mi Nei.
com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year.
According to data from Mi Nei.
com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year.
Mycophenolate mofetil is an immunosuppressant developed by Roche.
It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
Sales of mycophenolate mofetil at the terminal of public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2019, the sales of mycophenolate mofetil in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in 2020H1, its sales exceeded 1.
6 billion yuan, an increase of 13.
39% year-on-year, of which Roche accounted for 60.
7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
39%.
Hospital hospital hospital6 billion yuan, an increase of 13.
39% year-on-year, of which Roche accounted for 60.
7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
39%.
Mycophenolate mofetil capsules previously reviewed companies
Enterprise business enterprise Source: Mi Nei Net Consistency Evaluation Database
At present, mycophenolate mofetil capsules have been evaluated by 4 companies, including Hisun Pharmaceutical, Tianyin Pharmaceutical, Sino-US Huadong Pharmaceutical and Simcere Pharmaceutical.
With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
Data source: Mi Neiwang database
